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OBJECTIVES We sought to assess the effects of raloxifene, a selective estrogen receptor modulator, on
arterial physiology and biology in postmenopausal women with coronary artery disease
(CAD).
BACKGROUND Raloxifene improves endothelial function and markers of vascular health in vitro in
experimental animals and in healthy postmenopausal women. In women whose arteries are
affected by advanced atherosclerosis, however, the vascular effects of estrogen receptor
modulation are unknown.
METHODS We conducted a prospective, randomized, double-blinded, placebo-controlled, crossover trial
of raloxifene, 60 mg/day for 8 weeks, in 33 consecutively eligible and consenting postmeno-
pausal women age 50 to 75 years with known CAD. Parameters measured at the beginning
and end of each treatment period included brachial artery flow-mediated dilation (FMD), the
primary end point, as well as nitroglycerin-induced dilation, peripheral artery tonometry,
serum lipoprotein levels, and markers of vascular function, including urinary prostaglandin,
serum endothelin-1, and fibrinogen levels.
RESULTS Baseline FMD was impaired in these women, as expected (2.84  0.60%), but there was no
significant difference between the effect of raloxifene (0.26  0.66% increase) and placebo
(0.01  0.63% decrease) on this marker of endothelial function (p  0.82). No significant
raloxifene-related effects were observed on derived aortic pressure, pulse pressure, augmen-
tation index, total cholesterol or low- and high-density lipoprotein subfractions, markers of
thrombosis, or vasoconstrictor or vasodilator substances.
CONCLUSIONS In postmenopausal women with treated CAD, selective estrogen receptor modulation with
raloxifene does not improve a comprehensive set of parameters examining vascular function
and serum lipoprotein levels. (J Am Coll Cardiol 2003;42:698–704) © 2003 by the
American College of Cardiology Foundation
The marked gender difference between women and men
with respect to the development and progression of athero-
sclerosis, with epidemiologic studies showing less severe and
extensive disease in women (1,2), suggests the possibility of
estrogens protecting the cardiovascular system. Despite
promising effects on vascular function (3), lipoprotein levels
(4), and other intermediate markers of coronary risk (4,5),
clinical end-point studies of combined hormone replace-
ment (with estrogen and progesterone) in postmenopausal
women have not demonstrated any significant benefit (6).
Indeed, the recent publication of the Women’s Health
Initiative (WHI) study has suggested that the risk/benefit
ratio of combined hormone replacement does not support
the routine clinical use of this treatment for cardioprotection
after menopause (7), although the estrogen-only part of this
study is ongoing.
In this context, recent interest has focused on selective
estrogen receptor modulators, which agonize estrogen re-
ceptors in some tissues (e.g., liver, bone), but not in others
(e.g., breast, uterus). Raloxifene, for example, a benzothio-
phene derivative that binds to the estrogen receptor, im-
proves bone mineral density and lowers cholesterol levels in
postmenopausal women, without stimulating the endome-
trium (8). In human cells, raloxifene activates nitric oxide
(NO) synthesis via a nongenomic mechanism (9) and,
correspondingly, is known to vasodilate animal arteries via a
NO-dependent pathway (10). In healthy, older postmeno-
pausal women, raloxifene has been shown to improve
endothelial function, as well as increase NO and decrease
endothelin-1 levels (11).
The effect of raloxifene on the vasculature of older
postmenopausal women with coronary artery disease
(CAD) is important to understand in the context of possible
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secondary prevention. This question has not previously been
addressed. The situation might be expected to be different
in subjects with diseased versus healthy arteries, where the
effects of concomitant medications as well as advanced
atherosclerosis, per se, might alter the vascular responses to
selective estrogen receptor modulation. Data from the
Multiple Outcomes of Raloxifene Evaluation (MORE)
study (12) have suggested a cardiovascular benefit from
raloxifene treatment in older women at increased risk of
cardiovascular disease, whereas in the overall population, the
study suggested a neutral effect. Therefore, we undertook a
prospective, double-blinded, placebo-controlled study to
assess the effects of raloxifene treatment on vascular physi-
ology and biology in women with known CAD.
METHODS
Subjects. We recruited 33 consecutively eligible and con-
senting women age 50 to 75 years who were clinically stable
and asymptomatic but had documented evidence of CAD
(i.e., previously documented myocardial infarction, coronary
artery bypass graft surgery, and/or angiography showing at
least one coronary lesion with 70% stenosis). Eligible
subjects had had no menses for 18 months, had never
taken hormone replacement therapy (HRT), and had stable
use or non-use of lipid-lowering medications or antihyper-
tensive and/or antiplatelet therapy for at least six months
before the study. There had also been no change in their
smoking pattern for 6 months before the study. Subjects
were excluded if they had a history of regular therapy with
nitrates or clinical evidence of heart failure, intercurrent
Raynaud’s phenomenon, and/or a history of venous throm-
boembolism. Subjects were only included if their postmeno-
pausal status was confirmed by a serum follicle-stimulating
hormone level 40 IU/l at the screening visit. The subjects
were asked not to alter their medication for the duration of
the study, other than at the direction of their managing
physician. The institutional ethics committee approved the
study, and each woman gave written, informed consent.
Study design. Subjects were randomized to raloxifene or
matching placebo (Eli Lilly, Indianapolis, Indiana) in a
double-blinded, cross-over study. Each subject was seen on
five occasions. At the first visit (study screen), each partic-
ipant underwent a general physical examination and medical
history assessment, as well as follicle-stimulating hormone
measurement. Subjects returned for four further visits: at
baseline and after eight weeks of either raloxifene or
placebo, with a minimum four-week washout period be-
tween treatment regimes (Fig. 1). At each visit, subjects
presented at the same time of morning and had fasted since
10 PM on the previous night. Subjects also refrained from
taking any medications on the morning of the test, until
completion of the examination. Endothelium-dependent
and -independent dilation, peripheral artery tonometry,
heart rate, and blood pressure were measured as described
subsequently. Blood was collected and placed on ice for
biochemical studies (total cholesterol, low-density lipopro-
tein [LDL], and high-density lipoprotein [HDL] choles-
terol, triglycerides, lipoprotein[a], endothelin-1, antithrom-
bin III [AT III], fibrinogen), and urine was sampled for
prostacyclin metabolites and creatinine levels.
If eligible, subjects were randomized to receive either
raloxifene 60 mg/day or image-matched placebo for eight
weeks. Subjects were instructed to take one tablet each
morning, but to exclude the raloxifene or placebo tablet on
the day of their next visit to the study center (after eight
weeks). Compliance was estimated by return tablet counts.
Peripheral artery tonometry. Central arterial pressure,
waveform, and the degree of pulse pressure augmentation by
pulse wave reflection were studied noninvasively by sphyg-
mocardiography (PWV Medical Blood Pressure Analysis
System, Sydney, Australia) using applanation tonometry, as
described by Karamanoglu et al. (13). The aortic augmen-
tation index, aortic systolic pressure, and pulse pressure were
derived from the mean value of each of the three optimized
Figure 1. Study design: raloxifene and vascular reactivity.
Abbreviations and Acronyms
AT III antithrombin III
CAD  coronary artery disease
eNOS  endothelial nitric oxide synthase
FMD  flow-mediated dilation
GTN  glyceryl trinitrate
HDL  high-density lipoprotein
HRT  hormone replacement therapy
LDL  low-density lipoprotein
NO  nitric oxide
PGF1 2,3-dinor-6-keto-prostaglandin F1
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waveforms at each visit. The augmentation index was
calculated and expressed as the percent increase in aortic
pulse pressure between the second and first systolic peaks,
divided by the total pulse height.
Ultrasound studies. Following tonometry studies, brachial
artery reactivity was assessed by ultrasound using an ATL
HDI 5000 machine (Phillips, Bothell, Washington) with a
wide-band 12- to 5-MHz linear-array transducer. All stud-
ies were carried out at one site by one of two experienced
sonographers. We measured changes in brachial artery
diameter in response to reactive hyperemia-induced flow-
mediated dilation (FMD), the primary end point, and also
in response to glyceryl trinitrate (GTN), by scanning the
right brachial artery longitudinally 6 to 15 cm above the
elbow, as described in detail previously (14). A reliable
anatomic “marker” (vein, arterial branch, or muscle sheath)
was identified to allow reproducible location of the same
section of artery for each of the four visits for each subject.
All ultrasounds were recorded on super-VHS tape and
later analyzed by two independent observers who were
blinded to the identity of the subject, the stage of the
experiment, and the scan sequence. For calculation of FMD,
the vessel diameter at 45 to 60 s after cuff deflation was divided
by the average baseline diameter. We and other investigators
have previously demonstrated a high level of accuracy and
reproducibility under these test conditions (14).
Biochemical studies. SERUM LIPOPROTEINS. Total cho-
lesterol and triglycerides were measured by standard enzy-
matic methods, using a Hitachi 917 automatic analyzer. Levels
of HDL cholesterol were measured after precipitation with
dextran sulfate magnesium, and LDL cholesterol was calcu-
lated using the Friedewald equation. Lipoprotein(a) was mea-
sured using a Mercodia apolipoprotein A solid-phase, two-site
immunoradiometric assay (Mercodia AB, Uppsala, Sweden).
URINARY PROSTACYCLIN METABOLITES AND CREAT-
ININE. Urinary 2,3-dinor-6-keto-prostaglandin F1
(PGF1) was assayed by radioimmunoassay after extraction
and thin-layer chromatography, using a previously described
method (15). Urinary creatinine was measured using the
kinetic Jaffe reaction. Alkaline pictate was measured at 505
nm on the Hitachi 917 analyzer. The PGF1/creatinine
index was calculated as nanograms of PGF1/(mmol/l
creatinine  0.000113) and assigned arbitrary units, to
normalize this measure of systemic prostacyclin production
for renal function.
ENDOTHELIN-1. A commercially available sandwich
enzyme-linked immunosorbent assay (Biomedica, Vienna,
Austria) was used to measure endothelin-1 levels in ethylene
diamine-tetra acetic acid-plasma samples from blood col-
lected after each visit. Plasma stored at 70°C was thawed
and added to wells containing solid-phase mouse anti-
human endothelin-1 polyclonal antibody. Absorbance was
measured at 450 nm against 690 nm as a reference, using a
Sunrise Remote plate reader (Tecan, Gro¨dig, Austria). The
endothelin-1 standard curve was linear from 0 to 12.4
fmol/ml.
AT III AND FIBRINOGEN. Plasma AT III was measured
using a STA-Stachrom AT III chromogenic assay kit
(Diagnostica Stago, Asnie`res, France). Fibrinogen levels
were determined using the Clauss method (16).
Statistical analysis. Descriptive data are expressed as the
mean value  SEM. The prospectively defined primary end
point of this study was the change in FMD (post-treatment
minus pre-treatment values) on raloxifene versus placebo.
The changes on active and placebo treatments were com-
pared by the paired Student t test and corrected for multiple
comparisons (17,18). Baseline values before each treatment
were also compared by the paired t test corrected. The
treatment “order effect” was explored using standard regres-
sion techniques in terms of changes from baseline values for
all outcome variables. Statistical significance was inferred at
two-sided p  0.05, and comparisons used intention-to-
treat analyses.
The study power was calculated on an expected baseline
FMD of 4  0.5% (mean  SEM), based on our previous
studies in women with known CAD (19), as well as other
studies showing raloxifene to have no less than half of the
effect of conventional estrogen replacement on FMD
(20,21). Using these conservative estimates, this study of 33
women had over 90% power to detect a 3% improvement in
FMD at the two-sided p  0.05 significance level, using
data from our previous studies of measurement reproduc-
ibility (14). The study also had sufficient power (80%) to
detect changes in tonometric indexes and endothelin-1
levels, of the magnitude previously observed with raloxifene
and estrogen in healthy postmenopausal women (11,22).
RESULTS
Subjects. All 33 postmenopausal women enrolled in the
study (66  6 years old) completed both treatments arms,
with 96% compliance for raloxifene and 97% for placebo.
Baseline characteristics are listed in Table 1. There were no
major or minor adverse events reported throughout the
treatments, and all women were clinically stable and well.
All subjects had CAD documented by angiography, with
70% stenosis in at least one major epicardial artery.
Twenty-six subjects previously had coronary artery bypass
grafting, and 13 had percutaneous transluminal coronary
angioplasty before enrollment (3.1  0.4 years). Eighteen
subjects previously had a myocardial infarction. Seventeen
subjects had a history of hypertension, and five had non–
insulin-dependent diabetes mellitus. Thirteen subjects had a
family history of CAD in a first-degree relative55 years of
age. Of the 33 subjects included, 6 currently smoked and 7
were ex-smokers. The mean cigarette exposure in the
smokers was 13  4 pack-years. All 33 women in the trial
were taking cardioactive medications at the time of enroll-
ment (Table 2), but none changed drugs or dosages during
the treatment phases or washout period.
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Vascular reactivity studies. Baseline vessel diameter, blood
flow, and degree of reactive hyperemia after cuff release did
not alter significantly over the course of the study (Table 1).
Similarly, raloxifene treatment did not have a significant
effect on these parameters, as compared with placebo.
Multiple linear regression analysis did not reveal any “order
effect” in subjects randomly assigned to raloxifene treatment
before placebo. There was a small but not statistically
significant difference in FMD after treatment with ralox-
ifene (0.26  0.66% increase) compared with placebo (0.01
 0.63% decrease; p  0.82) (Fig. 2).
Furthermore, we did not find a significant difference in
GTN-mediated dilation after active treatment with ralox-
ifene (2.43  1.15% increase) compared with placebo (0.58
 1.00% increase). Similarly, raloxifene had no significant
effect on FMD or GTN responses when only the nonsmok-
ers (n  20) or current/former smokers (n  13) were
analyzed separately. In the entire subject group, neither
FMD nor GTN at baseline correlated significantly with the
baseline lipoprotein or blood pressure levels.
Tonometry. Aortic systolic blood pressure did not alter
throughout the course of the study (following raloxifene:
136  4 mm Hg; following placebo: 134  2 mm Hg).
Similarly, for raloxifene versus placebo, there were no
significant differences in pulse pressure (56  3 mm Hg vs.
55 2 mm Hg) or the augmentation index (32 1% vs. 33
 1%). There was no difference in the resting heart rate of
subjects due to treatment with raloxifene versus placebo (66
 2 beats/min vs. 65  2 beats/min). Brachial artery blood
pressure did not significantly alter throughout the study
(raloxifene: 144/76  4/2 mm Hg; placebo: 140/75  3/1
mm Hg).
Lipoproteins. Total cholesterol measured after raloxifene
was 4.7  0.1 mmol/l, as compared with 5.1  0.2 mmol/l
Table 2. Concomitant Medication Usage by the 33
Postmenopausal Women With Coronary Artery Disease
Medications n
Aspirin 28
Statins 27
ACE inhibitors 9
Beta-blockers 9
AT II receptor antagonists 4
Fish oil 2
Fibrates 1
ACE  angiotensin-converting enzyme; AT II  angiotensin II.
Table 1. Effects of Raloxifene and Placebo in Postmenopausal Women With Coronary Artery Disease
Raloxifene Placebo Change
Before After Before After Raloxifene (95% CI) Placebo (95% CI)
Baseline vessel diameter (mm) 3.56  0.09 3.38  0.09 3.48  0.10 3.50  0.08 0.18 (0.29 to 0.01) 0.02 (0.14 to 0.19)
Baseline blood flow (l/min) 66  9 60  8 65  7 63  7 6 (33 to 10) 2 (23 to 15)
Reactive hyperemia (%) 985  178 914  86 891  116 770  85 71 (446 to 369) 121 (291 to 197)
Flow-mediated dilation (%) 2.84  0.60 3.10  0.66 3.65  0.63 3.64  0.61 0.26 (0.65 to 1.15) 0.01 (1.38 to 1.36)
GTN-mediated dilation (%) 11.70  1.15 14.13  1.03 12.79  0.91 13.37  1.00 2.43 (0.30 to 4.56) 0.58 (1.53 to 2.69)
Aortic SBP (mm Hg) 138  3 136  4 132  3 134  2 2 (10 to 5) 2 (4 to 8)
Pulse pressure (mm Hg) 56  3 56  3 52  2 55  2 0 (5 to 5) 3 (2 to 8)
Augmentation index (%) 33  1 32  1 33  1 33  1 1 (2 to 1) 0 (2 to 2)
Heart rate (beats/min) 66  2 66  2 67  2 65  2 0 (4 to 3) 2 (4 to 1)
Brachial blood pressure
(mm Hg)
146/79  4/2 144/76  4/2 141/77  4/2 140/75  3/1 2/3 (9/7 to 7/1) 1/2 (8/6 to 6/2)
Total cholesterol (mmol/l) 4.9  0.2 4.7  0.1 5.0  0.2 5.1  0.2 0.2 (0.4 to 0.1) 0.1 (0.2 to 0.3)
LDL cholesterol (mmol/l) 2.7  0.1 2.5  0.1 2.8  0.2 2.8  0.1 0.2 (0.4 to 0.1) 0 (0.2 to 0.2)
HDL cholesterol (mmol/l) 1.37  0.06 1.29  0.06 1.37  0.06 1.36  0.07 0.08 (0.16 to 0.00) 0.01 (0.05 to 0.07)
Triglycerides (mmol/l) 1.9  0.1 2.0  0.1 1.8  0.1 2.0  0.2 0.1 (0.1 to 0.4) 0.2 (0.1 to 0.4)
Lipoprotein(a) (mg/l) 540  79 526  77 555  80 564  82 14 (62 to 34) 9 (38 to 38)
Fibrinogen (g/l) 3.7  0.1 3.3  0.1 3.7  0.1 3.6  0.1 0.4 (0.59 to 0.17) 0.1 (0.2 to 0.1)
Antithrombin III (IU/ml) 1.10  0.02 1.05  0.03 1.13  0.02 1.10  0.02 0.05 (0.10 to 0.01) 0.03 (0.08 to 0.02)
Endothelin-1 (fmol/ml) 1.02  0.24 1.10  0.27 1.17  0.21 1.20  0.25 0.08 (0.12 to 0.27) 0.03 (0.22 to 0.27)
PGF1/creatinine index (u) 514  107 460  78 504  77 427  64 54 (245 to 112) 77 (212 to 27)
Data are presented as the mean value  SEM. When comparing the change with raloxifene to that with placebo, there were no significant differences in any of the measured
parameters.
CI  confidence intervals; GTN  glyceryl trinitrate; HDL and LDL  high- and low-density lipoprotein; PGF1  2,3-dinor-6-keto-prostaglandin F1; SBP  systolic
blood pressure.
Figure 2. Effects of raloxifene and placebo on flow-mediated dilation
(FMD) in postmenopausal women with coronary artery disease.
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for placebo (p  NS) (Table 1). Levels of LDL cholesterol
after raloxifene (2.5  0.1 mmol/l) were similar to those
with placebo (2.8  0.2 mmol/l). Likewise, there was no
significant change in HDL cholesterol levels after raloxifene
(1.29  0.06 mmol/l), as compared with placebo (1.36 
0.07 mmol/l). Levels of triglycerides and lipoprotein(a)
remained unchanged throughout the study.
Hemostatic parameters. Fibrinogen was not significantly
affected by either treatment (following raloxifene: 3.3  0.1
g/l; placebo: 3.6  0.1 g/l). No change was observed in
plasma levels of AT III (raloxifene: 1.05  0.03 IU/ml;
placebo: 1.10  0.02 IU/ml).
Vasodilator/vasoconstrictor parameters. There was no
significant difference in levels of endothelin-1 measured
after each treatment (raloxifene: 1.10  0.27 fmol/l; pla-
cebo: 1.20  0.25 fmol/l), as compared with the corre-
sponding baseline values. Furthermore, the PGF1/
creatinine index was not significantly altered by either
treatment arms (following raloxifene: 460  78 U; placebo:
427  64 U).
DISCUSSION
In this study, we have found that clinically relevant doses of
raloxifene, shown to improve bone mineral density (8), as
well as vascular function (11) in healthy postmenopausal
women, had no measurable effect on markers of endothelial-
or smooth muscle-dependent dilator function, arterial pres-
sure waveform, blood pressure, serum lipoproteins, and
markers of thrombosis and vascular tone control when
administered for eight weeks to postmenopausal women
with known CAD.
The neutral finding of this study is surprising in the
context of previously published results. In vitro, raloxifene
has been shown to stimulate NO release rapidly from
cultured human endothelial cells, via nongenomic activation
of endothelial nitric oxide synthase (eNOS) (9). In experi-
mental animals, raloxifene dilates healthy rabbit coronary
arteries via an estrogen receptor- and NO-dependent path-
way (10). Similarly, raloxifene improves endothelial dys-
function in spontaneously hypertensive rats by increasing
NO release (23). Rapid relaxation has also been reported in
femoral veins from ovariectomized female pigs after treat-
ment with raloxifene (24). In healthy postmenopausal
women, raloxifene improves flow-mediated vasodilation of
the brachial artery (11), a NO-dependent response, consis-
tent with the in vitro findings in healthy human cells, as
described earlier.
The results of our study in women with CAD suggest
that the situation is different in the setting of advanced
atherosclerosis. This may be due to the effects of athero-
sclerosis itself and/or the effects of therapies used in its
treatment. Firstly, eNOS levels are markedly reduced in the
presence of atherosclerosis (25), potentially limiting the
beneficial effects that estrogen receptor modulation may
have via increasing NO production.
Secondly, many of the women in this study were taking
cardioactive medications, such as statins and/or antihyper-
tensive agents, including angiotensin-converting enzyme
inhibitors. Such treatments are well known to alter endo-
thelial function, vascular compliance, lipoprotein levels, and
vasodilator or vasoconstrictor bioavailability (26,27). We
aimed to assess the effects of raloxifene in women with
atherosclerosis in the presence of their normal treatment
regimens, not only for ethical reasons but also to mimic the
“real-life” situation in which any additional treatment for
“secondary prevention” would be prescribed.
Thirdly, it may be that our sample size was too small to
detect an important effect. By using a cross-over, placebo-
controlled design and estimating effect sizes from previous
publications reporting the effects of selective estrogen re-
ceptor modulators and HRT on the parameters measured in
the current study, our study was estimated to have 90%
power to demonstrate significant treatment-associated ef-
fects on the primary end point—arterial endothelial func-
tion—and similar power for many of the secondary end
points measured. Regarding some measurements, a rela-
tively small sample size may have had an impact on our
results. For example, raloxifene treatment was associated
with an approximate 10% fall in LDL cholesterol and
fibrinogen levels in our study, which were not statistically
significant results, but data consistent with the findings of
other larger studies (4,8).
It may also be possible that the length of time for active
treatment (eight weeks) was insufficient to confer beneficial
effect in these subjects. Still, eight weeks should indeed be
sufficient to measure significant changes in the major end
point—FMD— considering the apparent nongenomic
mechanism of action (i.e., increased eNOS activity), with no
accompanying increase in eNOS messenger ribonucleic acid
or protein synthesis (9). Furthermore, major studies of the
estrogen effects on vascular reactivity, even if via a genomic
effect on eNOS, have similarly utilized treatment durations
of several weeks only (20,21).
In this study, we measured a large number of parameters,
which reflect arterial health as “surrogate” end points. The
primary end point—arterial FMD—is well documented to
reflect endothelial NO release (28), a key mediator in
vascular health, and to be predictive of cardiovascular event
rates (29). Brachial FMD correlates well with coronary
endothelial function (30) and can be measured noninva-
sively and reproducibly (14), thereby lending itself to serial
study of treatment effects on vascular reactivity. Previous
studies using endothelial function as an end point, with
statins and angiotensin-converting enzyme inhibitors as
examples (31,32), have generally shown that treatments
associated with improved arterial endothelium-dependent
dilation are also associated with improved clinical outcomes
in large clinical end-point trials (33,34). Our study’s sec-
ondary end points were chosen to allow a comprehensive
assessment of vascular and serum parameters known to be
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related to atherothrombosis, such as arterial compliance,
lipoprotein levels, and markers of thrombosis.
Despite our neutral findings with raloxifene in older
women with atherosclerosis, Clarke et al. (35) have recently
documented that another selective estrogen receptor mod-
ulator—tamoxifen—increases FMD in men both with and
without obstructive stenoses on coronary angiography, as
well as decreasing lipoprotein and fibrinogen levels. We and
other investigators (36,37) have previously documented
important gender specificity of certain gender steroid-
related influences on the vasculature (i.e., marked differ-
ences in the vascular and cellular responses of men and
women to estrogens and androgens, related to differences in
cellular receptor numbers and function). It may be specu-
lated that such gender differences may also exist with regard
to responses to estrogen receptor modulators, just as there
may be differences in the characteristics of individual selec-
tive estrogen receptor modulators.
It has been suggested previously that raloxifene may be of
some benefit for the treatment of hypertension, especially in
patients with atherosclerosis, because of the other associated
beneficial effects of raloxifene treatment, such as increased
endothelium-dependent vasodilation (10,11). Indeed, blood
pressure levels have been significantly decreased in sponta-
neously hypertensive rats treated with raloxifene (23). The
results of our study, however, did not show any significant
effect on blood pressure, in either the 17 subjects studied
who had a history of hypertension, currently taking other
medications for controlling this, or in the 16 normotensive
subjects enrolled.
There are a number of published reports describing the
beneficial effects of raloxifene treatment on lipoprotein
profiles in healthy postmenopausal women. Raloxifene has
been shown to decrease total cholesterol, LDL cholesterol,
and lipoprotein(a) levels (8,38), factors which are well
established as independent risk factors for CAD. Levels of
HDL cholesterol and triglycerides, however, remain un-
changed by raloxifene in healthy postmenopausal women
(8,12,38). Despite these findings, which support a potential
beneficial role for raloxifene in reducing cardiovascular risk,
our study in women with established CAD has shown no
significant effects of raloxifene treatment on lipid profiles. A
significant contributing factor to the apparent lack of
positive effects on lipid profiles may be related to pharma-
cologic control of lipids in the majority of these subjects by
hydroxymethylglutaryl coenzyme A reductase inhibitors
and/or the relatively short duration of the active treatment
period.
Raloxifene is a member of the estrogen receptor modu-
lator family, a class of compounds introduced to avoid the
side effects of natural estrogen and progesterone treatments.
Raloxifene has been shown to be clinically effective for the
prevention of postmenopausal osteoporosis and to reduce
the risk of invasive breast cancer, with no apparent increase
in the risk of endometrial cancer, unlike with natural
estrogen therapies (39). Furthermore, conventional HRT is
associated with increased levels of C-reactive protein (5),
indicating possible proinflammatory effects. In contrast,
studies with raloxifene do not report an increase in plasma
C-reactive protein (4,5), suggesting no indication of inflam-
mation in healthy postmenopausal women as the result of
treatment. It has also been reported that serum homocys-
teine levels are lowered by raloxifene (5).
In contrast, the results of the current study do not
demonstrate important vascular effects of raloxifene treat-
ment in postmenopausal women with treated CAD. The
dosage used was similar to that in the more encouraging in
vitro animal and healthy human studies cited earlier. As the
subpopulation of high-risk women in the MORE study (12)
did appear to have lower cardiovascular event rates while on
raloxifene during follow-up, the place of this treatment in
cardiovascular protection awaits publication of the large,
ongoing Raloxifene Use for The Heart (RUTH) study (40),
examining the effects of raloxifene on clinical outcomes in
secondary as well as high-risk primary prevention.
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